PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
13.68%
Cash & equivalents yoy growth below half of TRAW's 152.33%. Michael Burry would question if the firm faces a liquidity squeeze. Check for rising debts or negative cash flow.
No Data
No Data available this quarter, please select a different quarter.
13.68%
Below half of TRAW's 152.33%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.59%
Below half of TRAW's 145.91%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-11.93%
≥ 1.5x TRAW's -5.77%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-88.66%
Higher Other Non-Current Assets Growth compared to TRAW's zero value, indicating worse performance.
-8.29%
≥ 1.5x TRAW's -1.49%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
13.10%
Below half of TRAW's 144.42%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-14.12%
Similar yoy growth to TRAW's -17.48%. Walter Schloss sees parallel payables strategy. Check top-line correlation.
2.34%
Higher Short-Term Debt Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
14.12%
Higher Deferred Revenue (Current) Growth compared to TRAW's zero value, indicating better performance.
-2.34%
Less than half of TRAW's -51.18%. David Dodd sees fewer expansions in other current obligations.
-12.65%
Less than half of TRAW's -26.89%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-36.66%
Less than half of TRAW's 15.30%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-14.12%
Similar yoy to TRAW's -15.31%. Walter Schloss sees parallel expansions in total liabilities.
5.56%
Less than half of TRAW's 1808.87%. David Dodd sees fewer share issuances vs. competitor.
-2.30%
≥ 1.5x TRAW's -1.10%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.36%
Below half TRAW's 501.67%. Michael Burry sees potential underperformance in building shareholder capital.
13.10%
Below half TRAW's 144.42%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-14.09%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
-14.00%
Less than half of TRAW's -152.33%. David Dodd sees better deleveraging or stronger cash buildup than competitor.